Inventor
Liang Liu
Inventor
Macau, CN
Overview
Patents· 51 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes37%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
G01NInvestigating or analysing materials by determining their chemical or physical properties7%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms5%
C07DHeterocyclic compounds3%
H04LTransmission of digital information, e.g. telegraphic communication3%
C07JSteroids2%
C07KPeptides2%
G05BControl or regulating systems in general2%
G05DSystems for controlling or regulating non-electric variables2%
PatentTitleYear
11,050,602Methods and communication apparatuses for bit-to-symbol mapping202111,040,710System and method for using human driving patterns to detect and correct abnormal driving behaviors of autonomous vehicles202111,039,454User terminal and radio communication method202111,029,693Neural network based vehicle dynamics model202111,019,349Content-based client side video transcoding202110,787,708Method of identifying a gene associated with a disease or pathological condition of the disease202010,702,500Methods of treating cancer202010,688,105Method of treating refractory rheumatoid arthritis associated with p53 mutation202010,493,118Triterpenoid obtainable from hedera helix for treatment of neurodegenerative diseases201910,322,097Treatment of subjects with multidrug-resistant cancer201910,278,955Methods of treating cancer201910,265,298Method of increasing the bioavailability of silybin201910,234,454Use of glycan as biomarkers for autoimmune diseases201910,220,064Carbohydrate composition extracted from 201910,208,028Methods of treating cancer201910,155,721Lignanamides and a method of treating neurodegenerative diseases by using the same201810,111,876ALK Kinase Inhibitor and its use20189,974,766Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer20189,962,378ROS1 inhibitor and its use20189,955,676Transgenic model for delay-type hypersensitivity (DTH) and use thereof20189,913,811'Hydroxynaphthoquinone compounds for treatment of non-small cell lung cancer'20189,901,566'Limonoids for treating autoimmune diseases'20189,884,046'Method of treating lung cancer'20189,884,047'Method of treating lung cancer'20189,861,623'Combination treatment of RAS-positive diseases with PDE-δ inhibitor and direct autophagy inhibitor'20189,855,250'Method to treat lung cancer'20189,808,439'Use of tangeretin in cancer treatment'20179,808,477'Use of nobiletin in cancer treatment'20179,782,400'Oncogenic ROS1 and ALK kinase inhibitor'20179,744,145'Methods for treating lung cancer'20179,675,608'Identification of natural small-molecules AMPK activators for treatment of cancers or multidrug-resistant cancers'20179,604,987'Synthesis of autophagy inducing compound and the uses thereof'20179,597,299'Method for treating gefitinib-resistant non-small-cell lung cancer'20179,561,223'Group of alkaloids, the novel autophagic enhancers for treatment of cancers and neurodegenerative conditions thereof'20179,561,219'Group of alkaloids, the novel autophagic enhancers for treatment of cancers and neurodegenerative conditions thereof'20179,561,221'Group of alkaloids, the novel autophagic enhancers for treatment of cancers and neurodegenerative conditions thereof'20179,561,222'Group of alkaloids, the novel autophagic enhancers for treatment of cancers and neurodegenerative conditions thereof'20179,561,220'Group of alkaloids, the novel autophagic enhancers for treatment of cancers and neurodegenerative conditions thereof'20179,526,722'Oncogenic ROS1 kinase inhibitor'20169,522,125'Method of treating cancer'20169,439,898'Methods for novel drug discovery, treatment and selective targeting for gefitinib-resistant non-small-cell lung cancer harboring T790M mutation'20169,375,457'Composition comprising Rhizoma coptidis, Cortex phellodendri and Fructus gardeniae and for treating neurodegenerative diseases'20169,364,469'Identification of a new AMPK activator for treatment of lung cancer'20169,273,088'Ginsenoside derivative compounds and the use thereof in protection against ischemia/reperfusion injury'20169,119,847'Neferine and the use thereof in treating huntington disease'20159,051,348'Ginsenoside with anti-cancer activity and the preparation method thereof'20159,018,196'Development of a new formulation overcoming thymus atrophy with concomitantly enhancement of anti-inflammatory effect of dexamethasone'20159,005,677'Autophagy enhancer for treatment of neurodegenerative diseases'20158,551,541'Disinfectant making air fresh and preparation and method and use thereof'20137,544,668'Saponins derived from Ilex pubescens and method of purifying the same'20097,419,960'Hemiterpene glycosides with anti-platelet aggregation activities from Ilex pubescens '2008Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2008–2016Patents assigned to UNIV HONG KONG BAPTIST (3)· patent assignee history
2009–2017Based in Hong Kong, CN· patent location history
2013Patents assigned to EVERITE CONSULTANTS LTD (1)· patent assignee history
2015–2020Patents assigned to UNIV MACAU SCI & TECH (41)· patent assignee history
2015–2020Based in Macau, CN· patent location history
2017–2020Based in Taipa, MO· patent location history
2021Patents assigned to NTT DOCOMO INC (2)· patent assignee history
2021Patents assigned to TUSIMPLE INC (2)· patent assignee history
2021Based in Beijing, CN· patent location history
2021Based in San Diego, CA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV MACAU SCI & TECH | 41 | 2015–2020 |
| UNIV HONG KONG BAPTIST | 3 | 2008–2016 |
| NTT DOCOMO INC | 2 | 2021 |
| TUSIMPLE INC | 2 | 2021 |
| EVERITE CONSULTANTS LTD | 1 | 2013 |
Locations
| Location | Patents | Span |
|---|---|---|
| Macau, CN | 25 | 2015–2020 |
| Taipa, MO | 12 | 2017–2020 |
| Hong Kong, CN | 4 | 2009–2017 |
| Beijing, CN | 2 | 2021 |
| San Diego, California, US | 2 | 2021 |